Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (371-380 of 445) with videos related to

Pageof 45
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
Cell Reports. Medicine|April 8, 2023
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilitiesNaiara Perurena, Rebecca Lock, Rachel A Davis, et al.
Breast (Edinburgh, Scotland)|February 28, 2026
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trialKatie E Johnston, Kate O'Connell, Laia Raigal-Aran, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 23, 2021
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomesVishwajith Sridharan, Mari Mino-Kenudson, James M Cleary, et al.
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
The Oncologist|February 19, 2021
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS TrialAminah Jatoi, Fang-Shu Ou, Daniel H Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Pageof 45

Showing results (371-380 of 445) with videos related to

Sort By:
Pageof 45
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
NPJ Precision Oncology|August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumorsAaron S Mansfield, David S Hong, Christine L Hann, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
Cell Reports. Medicine|April 8, 2023
USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilitiesNaiara Perurena, Rebecca Lock, Rachel A Davis, et al.
Breast (Edinburgh, Scotland)|February 28, 2026
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trialKatie E Johnston, Kate O'Connell, Laia Raigal-Aran, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|May 23, 2021
Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomesVishwajith Sridharan, Mari Mino-Kenudson, James M Cleary, et al.
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
The Oncologist|February 19, 2021
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS TrialAminah Jatoi, Fang-Shu Ou, Daniel H Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
Pageof 45